Psoriasis Drug, Taltz – FDA approved

New and promising Psoriasis Drug, Taltz wins FDA approval.

Psoriasis drug, taltz

Taltz (ixekizumab), a biologic injectable drug manufactured by the drug maker Eli Lilly, won FDA approval for the treatment of moderate-to-severe plaque psoriasis.

The clinical trials have shown that the psoriasis drug, Taltz can improve psoriasis by at least 75 percent after three months in more than 80 percent of people taking the drug, and completely clear skin to up to about 35 percent of patients in the same period of time.

Have you tried other biologics and got no or little results?

The trial also showed that almost 84 percent of those who switched to Taltz saw 75 percent improvement after three months. Results also showed that more than 20 percent had completely clear skin in the same amount of time.

Read more about the psoriasis drug, Taltz by the National Psoriasis Foundation.


Please check out our website for more information about new clinical studies or call us at 855-554-6374.